p53 mutations in multiple urothelial carcinomas: A molecular analysis of the development of multiple carcinomas

Modern Pathology

Volumn 10, Issue 5, 1997, Pages 428-437

  Goto, Ken ^a   Konomoto, Tatsuo ^a   Hayashi, Kenshi ^b   Kinukawa, Naoko ^a   Naito, Seiji ^a   Kumazawa, Joichi ^a   Tsuneyoshi, Masazumi ^a,b  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Multiple; Origin; p53; SSCP; Urothelial carcinoma

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; DNA SEQUENCE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY PELVIS CARCINOMA; MALE; MULTIPLE CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; URETER CARCINOMA; UROGENITAL TRACT CANCER;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; POINT MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUMOR SUPPRESSOR PROTEIN P53; URETERAL NEOPLASMS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0030919762     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Fair WR, Fuks ZY, Scher HI. Cancer of the Bladder. In: De Vita VT Jr, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th ed. Vol 1. Philadelphia: Lippincott, 1993:1052-72.
2. Harris AL, Neal DE. Bladder cancer - field versus clonal origin. N Engl J Med 1992;326:759-61.
3. Rao JY, Hemstreet GP III, Hurst RE, Bonner RB, Jones PL, Min KW, et al. Alterations in phenotypic biological markers in bladder epithelium during tumorigenesis. Proc Natl Acad Sci U S A 1993;90:8287-91.
4. Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. N Engl J Med 1992;326:737-40.
5. Lunec J, Challen C, Wright C, Mellon K, Neal DE. c-erbB-2 amplication and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder. Lancet 1992;339:439-40.
6. Habuchi T, Takahashi R, Yamada H, Kakehi Y, Sugiyama T, Yoshida O. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 1993;342:1087-8.
7. Miyao N, Tsai YC, Lerner SP, Olumi AF, Spruck CH III, Gonzalez-Zulueta M, et al. Role of chromosome 9 in human bladder cancer. Cancer Res 1993;53:4066-70.
8. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54: 4855-78.
9. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994;54: 784-8.
10. Fujimoto K, Yamada Y, Okajima E, Kakizoe T, Sasakj H, Sugimura T, et al. Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 1992;52:1393-8.
11. Hermanek P, Sobin LH. UICC (International Union Against Cancer). TNM classification of malignant tumors. 4th ed. Berlin: Springer-Verlag, 1987.
12. Mostfi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumors. Geneva: World Health Organization, 1973.
13. Mostfi FK, Sesterhenn IA, Torloni LH. Histological typing of kidney tumors. Geneva: World Health Organization, 1981.
14. Goelz SE, Hamilton SR, Vogelstein B. Purification of DNA from formaldehyde-fixed and paraffin-embedded human tissue. Biochem Biophys Res Commun 1985;130:118-26.
15. Suzuki Y, Sekiya T, Hayashi K. Allele-specific polymerase chain reaction: a method for amplification and sequence determination of a single component among a mixture of sequence variants. Anal Biochem 1991;192:82-4.
16. Li ZH, Zheng J, Weiss LM, Shibata D. c-K-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol 1994;144:303-9.
17. Nees M, Homann N, Discher H, Andl T, Enders C, Herold-Mende C, et al. Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res 1993;53:4189-96.
18. Strickler JG, Zheng J, Shu Q, Burgart LJ, Albert SR, Shibata D. p53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res 1994;54:4750-5.
19. Bennett WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu S, et al. p53 Mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 1992;52:6092-7.
20. Kanjilal S, Strom SS, Clayman GL, Weber RS, El-Naggar WA, Kapur V, et al. p53 Mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res 1995;55:3604-9.
21. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavance W, Vogelstein B. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992;355:846-7.
22. Oda T, Tsuda H, Sakamoto M, Hirohashi S. Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as a evidence for multistage progression. Cancer Lett 1994;83:197-200.
23. Konishi N, Hiasa Y, Matsuda H, Tao M, Tsuzuki T, Hayashi I, et al. Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor supressor gene in human prostate carcinoma. Am J Pathol 1995;147:1112-22.
24. Oda H, Nakatsuru Y, Ishikawa T. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas. Cancer Res 1995;55:658-62.
25. Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252:706-9.
26. Uchida T, Wada C, Ishida H, Wang C, Egawa S, Yokoyama E, et al. p53 Mutations and prognosis in bladder tumors. J Urol 1995;153:1097-104.
27. Williamson MP, Elder PA, Knowles MA. The spectrum of TP 53 mutations in bladder carcinoma. Genes Chromosom Cancer 1994;9:108-18.
28. Soini Y, Turpeenniemi-Hujanen T, Kamel D, Autio-Harmainen H, Risteli J, Risteli L, et al. p53 Immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br J Cancer 1993;68: 1029-35.
29. Wagner U, Sauter G, Moch H, Novotna H, Epper R, Mihatsch MJ, et al. Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. Hum Pathol 1995;26:970-8.
30. Sarkins AS, Dalbagni G, Cordon-Cardo C, Zhang Z, Sheinfeld J, Fair WR, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53-9.
31. Sawada M, Azuma C, Hashimoto K, Noguchi S, Ozaki M, Saji F, et al. Clonal analysis of human gynecologic cancers by means of the polymerase chain reaction. Int J Cancer 1994; 58:492-6.
32. Tsuda H, Oda T, Sakamoto M, Hirohashi S. Different pattern of chromosomal allele loss in multiple hepatocellular carcinomas as evidence of their multifocal origin. Cancer Res 1992;52:1504-9.
33. Kusser WC, Miao X, Glickman BW, Friedland JM, Rothman N, Hemstreet GP, et al. p53 Mutations in human bladder cancer. Environ Mol Mutagen 1994;24:156-60.
34. Oyasu R, Nan L, Szumel RC, Kawamata H, Hirohashi S. p53 gene mutations in human urothelial carcinomas: analysis by immunohistochemistry and single-strand conformational polymorphism. Mod Pathol 1995;8:170-6.
35. Hayashi K. PCR-SSCP: a method for detection of mutations. Genet Anal Tech Appl 1992;9:73-9.
36. Gonzalez-Zulueta M, Ruppert JM, Tokino K, Tsai YC, Spruck CH III, Miyao N, et al. Microsatellite instability in bladder cancer. Cancer Res 1993;53:5620-3.
37. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, et al. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996;24:141-6.
38. Hongyo T, Buzard GS, Palli D, Weghorst CM, Amorosi A, Galli M, et al. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence Italy. Cancer Res 1995;55:2665-72.
39. Shiao Y, Chen VW, Scheer WD, Wu XC, Correa P. Racial disparity in the association of p53 gene alterations with breast cancer survival. Cancer Res 1995;55:1485-90.
40. Rideout WM III, Coetzee GA, Olumi CA, Jones PA. 5-Methylcytosine as an endogeneous mutagen in the human LDL receptor and p53 genes. Science 1990;249:1288-90.
41. Petersen I, Ohgaki H, Ludeke BI, Kleihues P. p53 Mutations in phenacetin-associated human urothelial carcinomas. Carcinogenesis 1993;14:2119-22.
42. Kinoshita T, Ueda M, Enomoto K, Ikeda T, Kikuchi K, Ishii S, et al. Comparison of p53 gene abnormalities in bilateral and unilateral breast cancer. Cancer 1995;76:2504-9.
43. Spruck CH III, Rideout WM III, Olumi AF, Ohneseit PF, Yang AS, Tsai YC, et al. Distinct pattern of p53 mutations in bladder cancer, relationship to tobacco usage. Cancer Res 1993;53:1162-6.
44. Habuchi T, Takahashi R, Yamada H, Ogawa O, Kakehi Y, Ogura K, et al. Influence of cigarette smoking and schistosomiasis on p53 gene mutation in urothelial cancer. Cancer Res 1993;53:3795-9.